Furthermore, evolving insights into dynamic risk modifiers (e.g., transient anemia, fluctuating blood pressure, or concomitant antiplatelet use) and biomarker-driven approaches [e.g., growth differentiation factor-15 (GDF-15) or high-sensitivity troponin] have catalyzed the development of next-generation RAMs (13, 14). This evidence concerns the gene GDF15 and anemia.